Celldex (CLDX) Prices 13.378M Share Common Offering at $9.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall Street indexes fall, with Iran and earnings season in focus
- NVIDIA reports 9.3% passive stake in Nebius
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
After-Hours Stock Movers 06/15: (WW) (MBIO) (VRAY) Higher; (CLDX) (AVEO) (AAXN) Lower (more...)
June 15, 2020 5:41 PM EDTToday's After-Hours Stock Movers
Weight Watchers International, Inc. (NASDAQ: WW) 12.3% HIGHER; had 4.9 million subscribers as of June 6, 2020, up 7%; Amends Revolving Credit Facility
Celldex Therapeutics, Inc. (NASDAQ: CLDX) 5.7% LOWER; announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30day... More
Celldex (CLDX) Announces Proposed Common Share Offering
June 15, 2020 4:04 PM EDTCelldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30day option to purchase up to an... More
Celldex Therapeutics (CLDX) PT Raised to $12 at Cantor Fitzgerald After Positive CDX-0159 Data
June 12, 2020 6:33 AM EDTCantor Fitzgerald analyst Kristen Kluska raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $12.00 (from $8.00) after including the CDX-0159 data that were presented on 6/6 and shifting to a DCF based model. Shares rose 193% over the last two days, in part, due to insider buying... More
